BioXcel Holdings Inc. 13D and 13G filings for BioXcel Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-10-19 4:48 pm Unchanged |
2023-09-19 | 13G | BioXcel Therapeutics, Inc. BTAI |
BioXcel Holdings Inc. | 556,359 30.100% |
0 (Unchanged) |
Filing |
| 2023-04-04 06:00 am Sale |
2023-04-03 | 13G | BioXcel Therapeutics, Inc. BTAI |
BioXcel Holdings Inc. | 556,359 30.300% |
-34,395 (-5.82%) |
Filing |
| 2023-02-14 4:36 pm Purchase |
2022-12-31 | 13G | BioXcel Therapeutics, Inc. BTAI |
BioXcel Holdings Inc. | 590,755 32.700% |
8,376 (+1.44%) |
Filing |
| 2022-02-14 4:57 pm Sale |
2021-12-31 | 13G | BioXcel Therapeutics, Inc. BTAI |
BioXcel Holdings Inc. | 582,378 32.400% |
-19,809 (-3.29%) |
Filing |
| 2021-02-16 5:14 pm Purchase |
2020-12-31 | 13G | BioXcel Therapeutics, Inc. BTAI |
BioXcel Holdings Inc. | 602,188 38.590% |
602,188 (New Position) |
Filing |